Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.47 |
| ▸ | KIT | P10721 | 4/20 | 0.47 |
| ▸ | FLT1 | P17948 | 4/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.45 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194742 | 0.87 | ABL1 (0.47) | ABL1MTNR1AMTNR1B | |
| SCHEMBL2192163 | 0.85 | ABL1 (0.45) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL2192527 | 0.83 | KDR (0.55) | KDRPDGFRBKITFLT1ABL1 | |
| SCHEMBL2189841 | 0.83 | NPC1 (0.47) | KDRABL1MTNR1AMTNR1BRIPK1 | |
| SCHEMBL2192794 | 0.81 | ALDH1A1 (0.52) | KDRBRAFMAPT | |
| SCHEMBL2191687 | 0.81 | ABL1 (0.42) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL2194095 | 0.80 | BRAF (0.57) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL2195154 | 0.80 | BRAF (0.64) | KDRBRAFKMT2A | |
| SCHEMBL2194492 | 0.78 | SMN1; SMN2 (0.55) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL3245490 | 0.77 | KDR (0.53) | KDRPDGFRBKITFLT1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181987-B9 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2181987-B1 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8324395-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2181987-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | KDR 843/4885PDGFRB 2265/4885KIT 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.